Clinical trials: Breast Cancer, Breast Neoplasms
Ductal Carcinoma in Situ - Category, Breast Cancer
Study to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction
The investigators hypothesize that nipple-areola skin sparing mastectomy (NASSM) performed through an inframammary incision has a superior blood supply relative to a lateral oblique incision.
- Conditions
- Ductal Carcinoma in Situ - Category, Breast Cancer, Prophylactic Mastectomy
- Trial name
- NASSM (NCT01969448)
- Testing
- Inframammary Fold Incision or Lateral Radial Incision, Lateral Radial Incision, Inframammary Fold Incision
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Washington University School of Medicine
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Breast Cancer WEight Loss Study (BWEL Study)
This randomized phase III trial compares whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence).
- Conditions
- Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
- Trial name
- NCT02750826
- Testing
- Health Education Program, Weight Loss Intervention
- Where
- 1,498 sites in United States, Canada and 2 more
- Volunteers
- 3,177 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Carcinoma
One Week Adjuvant Radiotherapy for Breast Cancer
Cancer is the second leading cause of death after cerebrovascular strokes and is a significant obstacle to each nation's future growth.
- Trial name
- NCT05150535
- Testing
- Hypofractionation Radiotherapy., Ultra-hypofractionation radiotherapy
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Breast Neoplasms
Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer
PF-04691502 is an inhibitor of PI3K and mTOR kinase. Exemestane is an aromatase inhibitor for the treatment of advanced breast cancer in women whose disease has progressed following tamoxifen therapy.
- Trial name
- NCT01658176
- Testing
- PF-04691502, Exemestane
- Sponsor
- Pfizer
Breast Cancer
Cosmetic Result/Toxicity in Post-Mastectomy Immediate Reconstruction Expander+RT
This research study is being done to carefully evaluate the effect of giving radiation therapy after temporary breast reconstruction.
- Trial name
- NCT01664091
- Testing
- post-mastectomy radiation therapy (PMRT), tissue expander (TE), acellular dermal matrix (ADM)
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Breast Carcinoma
Impact of Tumor Bed Localisation on Dosimetry Boost Irradiation in Patients Undergoing Breast Conserving Surgery
PRIMARY STUDY OBJECTIVES: To evaluate dosimetric outcomes in tumor bed boost irradiation in patients undergoing breast conservative surgery using three different surgical techniques SECONDARY OBJECTIVES- Evaluation of cosmesis in…
- Trial name
- NCT03710018
- Where
- India
- Volunteers
- 21 people
- Sponsor
- Tata Memorial Centre
Breast Cancer Metastatic
HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity
The study will be conducted as an open-label, single-center, Phase II clinical study, with a planned enrollment of 86 patients with locally advanced or metastatic HER2-positive and HER2-low breast cancer who are intended to…
- Trial name
- PREDICT-HER (NCT07586215)
- Testing
- PET
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Triple Negative Breast Cancer, Chemotherapy Effect
The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer
Introduction: Most cases of Triple Negative Breast Cancer (TNBC) have a high proliferation rate. TNBC is associated with a poor prognosis, a high recurrence rate, and a high incidence of distant metastases.
- Conditions
- Triple Negative Breast Cancer, Chemotherapy Effect, Simvastatin Adverse Reaction
- Trial name
- NCT05550415
- Testing
- Simvastatin 40mg
- Where
- Indonesia
- Volunteers
- 26 people
- Sponsor
- Universitas Indonesia
Neoplasms, Breast Neoplasms
A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
This study is comprised of two portions: a Phase 1 portion and a Phase 2 portion. The Phase 1 portion is a single-country, non-randomized, open label, clinical trial which will evaluate the safety, tolerability, preliminary…
- Trial name
- NCT01684215
- Testing
- PD-0332991, letrozole
- Where
- 16 sites in Japan
- Volunteers
- 61 people
- Sponsor
- Pfizer
Breast Cancer
Study of Preoperative Boost Radiotherapy
This protocol seeks to utilize a novel method of tumor bed boost delivery and to better understand breast cancer radiation response through the analysis of pre-and post-radiation breast tumor samples.
- Trial name
- NCT02482389
- Testing
- Single fraction of 7 Gy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
Breast Cancer, HER2 + Breast Cancer
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
The aim of this study is to evaluate the efficacy and safety of TQB2102 compared to TCbHP in the neoadjuvant treatment of HER2-positive breast cancer.
- Trial name
- NCT07136974
- Testing
- TQB2102, Docetaxel + Carboplatin + Trastuzumab +Pertuzumab
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Henan Cancer Hospital
Breast Neoplasms
Proton Magnetic Resonance Spectroscopy of Normal Breast Tissues in Women Volunteers
Magnetic resonance spectroscopy (MRS) is a diagnostic technique in MRI that distinguishes various metabolites on the basis of their slightly different chemical shifts or resonance frequencies.
- Trial name
- NCT00155090
- Where
- Taiwan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Breast Cancer
Sentinel Lymph Node Biopsy in Patients With Breast Cancer After Neoadjuvant Therapy
The aim of this study is to create clear indications for Sentinel Lymph Node Biopsy (SLNB) or Axillary Dissection (AD) in women with breast carcinoma after neoadjuvant therapy by studying the false negative rate of SLNB.
- Trial name
- NCT03556397
- Testing
- Sentinel lymph node biopsy (SLNB), Axillary dissection
- Where
- 2 sites in Czechia
- Volunteers
- 61 people
- Sponsor
- University Hospital Ostrava
Breast Cancer
Exercise, Fitness and Tumor Profiling in Breast Cancer Patients
This study is designed to find out how engaging in regular exercise (or not) alters the biology of breast tumors as well as the normal tissue (if available) surrounding the tumor.
- Trial name
- NCT03424915
- Testing
- Harvard Health Professionals survey, Blood draw, CPET Procedures
- Where
- 7 sites in United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments
Electronic health records (EHRs) are an increasingly common source for populating risk models, but whether used to populate validated risk assessment models or to de-facto build risk prediction models, EHR data presents several…
- Trial name
- FHIR (NCT05810025)
- Testing
- RealRisks
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Columbia University
Breast Cancer
Partial Breast Irradiation Using Accelerated Intensity Modulated Radiotherapy
This is a phase I- II feasibility study for delivering partial breast irradiation (PBI) in selected patients with early stage, lymph node negative, breast cancer after breast-conserving surgery using accelerated Intensity…
- Trial name
- NCT00581529
- Testing
- IMRT
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Michigan Rogel Cancer Center
Invasive Breast Cancer, Ductal Carcinoma in Situ
Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer
The primary objective of this study is to identify the group of women with early stage breast cancer most likely to benefit from treatment with the selective progesterone receptor modulator (SPRM) mifepristone.
- Trial name
- NCT01138553
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, San Diego
Breast Cancer, Physical Activity
Tracking Physical Activity Throughout Chemotherapy for Breast Cancer
Physical activity during chemotherapy has been shown to increase patient health and wellbeing as well as improve outcomes in breast cancer patients.
- Trial name
- NCT03041545
- Testing
- Fitbit
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of California, San Diego
Breast Cancer
A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer
This 2 arm study assessed the safety and efficacy of adding intravenous trastuzumab (Herceptin®) to daily oral anastrozole (Arimidex®) tablets as first- and second-line treatment in postmenopausal patients with human epidermal…
- Trial name
- NCT00022672
- Testing
- trastuzumab (Herceptin®), anastrazole (Arimidex®)
- Where
- 132 sites in United States, Australia and 24 more
- Volunteers
- 208 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.